APA (7th ed.) Citation

J, G., A, H., L, G., A, S., A, R., L, V., . . . E, G. (2023). Open-label phase II clinical trial of ketoconazole as CYP17 inhibitor in metastatic or advanced non-resectable granulosa cell ovarian tumors: The GREKO (GRanulosa Et KetOconazole) trial, GETHI 2011-03. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 25(7), 2090. https://doi.org/10.1007/s12094-023-03085-w

Chicago Style (17th ed.) Citation

J, Garcia-Donas, et al. "Open-label Phase II Clinical Trial of Ketoconazole as CYP17 Inhibitor in Metastatic or Advanced Non-resectable Granulosa Cell Ovarian Tumors: The GREKO (GRanulosa Et KetOconazole) Trial, GETHI 2011-03." Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 25, no. 7 (2023): 2090. https://doi.org/10.1007/s12094-023-03085-w.

MLA (9th ed.) Citation

J, Garcia-Donas, et al. "Open-label Phase II Clinical Trial of Ketoconazole as CYP17 Inhibitor in Metastatic or Advanced Non-resectable Granulosa Cell Ovarian Tumors: The GREKO (GRanulosa Et KetOconazole) Trial, GETHI 2011-03." Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, vol. 25, no. 7, 2023, p. 2090, https://doi.org/10.1007/s12094-023-03085-w.